SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex ...
WCVB Channel 5 Boston

Massachusetts hospitals face surgery disruptions due to national IV fluid crisis

NEXT WEEK ARE NOW GOING TO BE DELAYED. I.V. FLUID IS LIKE A LIFELINE TO PATIENTS. THAT LIFELINE IS IN SHORT SUPPLY AND NOW IMPACTING PATIENTS WHO HAVE NON-EMERGENCY SURGERIES SCHEDULED AT MASS.